Previous Close | 1.4500 |
Open | 1.4100 |
Bid | 1.3500 x 1800 |
Ask | 1.5500 x 3000 |
Day's Range | 1.4100 - 1.5200 |
52 Week Range | 0.4800 - 13.8000 |
Volume | |
Avg. Volume | 3,281,024 |
Market Cap | 39.693M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.0390 |
Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.13 |
Joining me on today's call is David Roman, chief executive officer and chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call do not relate to matters of historical fact should be considered forward-looking statements.
CARLSBAD, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2022. Recent Updates: Reported revenue of $4.1 million in the second quarter of 2022, compared to $3.7 million in the first quarter of 2022, and $4.7 million in the same quarter last year.Global mapping procedures volumes inc
CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in July 2022. The equity awards